{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-23-087129","form_type":"8-K","ticker":"ADIL","cik":"0001513525","company_name":"ADIAL PHARMACEUTICALS, INC.","filed_at":"2023-11-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.324289+00:00","generated_at":"2026-06-08T03:30:23.284826+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Adial Pharma Q3 net loss narrows to $1.4M; $4M private placement extends runway into Q4 2024","bullets":["Net loss $1.4M in Q3 2023, down 55% from $3.1M in Q3 2022.","R&D expenses decreased $489K (70%) YoY as AD04 trial activities wound down.","G&A expenses decreased $708K (38%) YoY due to lower compensation and headcount.","Cash $315K at Sep 30; $4M private placement (net $3.5M) completed post-quarter extends runway into Q4 2024.","Planning two parallel Phase 3 trials for AD04; in confidentiality agreements with potential partners."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-23-087129","json":"https://secwatch.observer/filing/0001213900-23-087129.json","markdown":"https://secwatch.observer/filing/0001213900-23-087129.md","text":"https://secwatch.observer/filing/0001213900-23-087129.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1513525/000121390023087129/0001213900-23-087129-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1513525/000121390023087129/ea188439-8k_adialpharma.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T03:30:23.284826+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"9666bedb74901d677eef9c893bc23299fc944f3d","claim":"ADIAL PHARMACEUTICALS, INC. reported the third quarter of 2023 results: net income Net Loss was $1.4 million for the three months ended September 30, 2023.","evidence_excerpt":"Adial Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1513525/000121390023087129/0001213900-23-087129-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter of 2023"},{"label":"Net income","value":"Net Loss was $1.4 million for the three months ended September 30, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}